NCT06783153Not yet recruitingPhase 1/2
Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients
Source: ClinicalTrials.gov · Last updated 20 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Preclinical data indicate that rifaximin could be repurposed as a novel strategy for preventing and reducing the severity of gastrointestinal damage, particularly diarrhea, that results from pelvic irradiation. So, The aim of the work is to investigate the impact of Rifaximin on the incidence and severity of radiotherapy-induced diarrhea in cancer patients undergoing pelvic irradiation with or without chemotherapy.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1/2
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 14 Jan 2025
- Start date
- 20 Jan 2025
- Primary completion date
- Dec 2025
- Lead sponsor
- Mansoura University
- Diseases
- Prostate cancer, Colorectal cancer
- NCT number
- NCT06783153
What you commit to
- Study type: Interventional · Phase 1/2
- Planned participants: 80
- From 20 Jan 2025 to the primary completion date, Dec 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have a record of intestinal resection in their medical history.
- Patients who regularly take anti-diarrheal medications before commencing radiotherapy.
Other illness
- Patients with a medical background of irritable bowel syndrome.
- Patients with a history of inflammatory bowel disease.
- Patients with compromised immune systems, such as those who are HIV positive or using immunosuppressive medications.
- Patients allergic to rifamycin.
Other
- Patients experiencing diarrhea at the outset of the study.
- Pregnant or lactating woman.
Who the study is looking for
- Individuals who are 18 years of age or older and have been diagnosed with non metastatic pelvic cancers.
- Patients who are undergoing curative intent radiotherapy with or without chemotherapy treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mansoura University Coordinator of this site? Confirm its status | Al Mansurah | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.